ALK and inflammatory myofibroblastic tumor: Other case reports revealed that ALK-translocated inflammatory myofibroblastic tumors (IMT) [14] and ALK-positive anaplastic large cell lymphoma (ALCL) showed encouraging response rates to crizotinib, including completely responding patients [15,16,17].